ArticleNeurocritical care2026
Biomarker Differences in Aneurysmal Subarachnoid Hemorrhage: A Comparative Study of Patients with and Without Delayed CEREBRAL Ischemia.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDelayed cerebral ischemia (DCI) is a major cause of morbidity following aneurysmal subarachnoid hemorrhage (aSAH), yet early prediction remains challenging. This study aimed to identify blood-based protein biomarkers within 24 h of intensive care unit admission associated with DCI using high-throughput proteomics.
methodsWe conducted a prospective longitudinal study including 86 patients with aSAH, of whom 28 developed DCI. For this exploratory analysis, we matched eight patients who developed DCI with eight controls without DCI based on age, sex, and severity scores. Plasma samples were analyzed using the Olink Explore 3072 platform targeting 2,943 proteins. Differential expression analysis was performed using linear Bayesian models with false discovery rate correction.
resultsWe identified 15 significantly dysregulated proteins (P < 0.01) in patients with DCI. Key downregulated proteins included THSD1, CA3, and PROK1, which are associated with vascular integrity and endothelial function. Upregulated proteins included BGN, IFNG, and CSF2, which are related to innate immunity and neuroinflammation. Novel candidates, such as CLSTN3 and DOCK9, also showed altered expression. Protein-protein interaction and gene ontology enrichment analyses revealed involvement in inflammatory, immune, and metabolic pathways.
conclusionsOur findings suggest a distinct early molecular signature in patients with aSAH who develop DCI, characterized by proinflammatory and neurovascular dysfunction markers. These candidate biomarkers warrant further validation in larger cohorts and may provide preliminary insight into biological processes associated with DCI. Their potential clinical value will require confirmation in independent studies.
Indexed as
Identifiers
41266703What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.